Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Closer Look: Why Are Indian Pharma Promoters Diversifying Into Other Sectors?

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Earlier this month when Piramal Healthcare Ltd.'s Chairman Ajay Piramal announced a foray into the financial services sector, local pharma watchers were reminded of the much-touted "game-changing" deal that the scion of Ranbaxy Laboratories Ltd. Malvinder Singh struck with Daiichi Sankyo three years ago

You may also be interested in...



Indian Firms Need To Change Management Style, Focus On Innovation To Grow, Say Execs

A workshop of senior executives deliberated on the next growth phase for Indian pharmaceutical companies and most came up with transformational ideas.

Analysts Question Sun Pharma’s Future Investment Plans As Former CFO Invests In Telenor

Analysts are divided on whether Sudhir Valia’s investments in Telenor’s new India joint venture may prove to be a backdoor way to indirectly channel funds from Sun Pharma.

Lupin Categorically Denies Sell-off Talks Amid Speculation Of $1 Billion Valuation For India Business

MUMBAI - Could Lupin Ltd. be the next to sell off its India business to a multinational drug company? Sources report that Lupin is considering selling its India business for a deal valued at as much as $1 billion, and several market analysts in India say the question is not without merit

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC077955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel